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Background: In various regions of Brazil, several species of the genus Byrsonima (Malpighiaceae) are widely used to
treat gastrointestinal complications. This genus has about 150 species of shrubs and trees distributed over the
entire Neotropical region. Various biological activities have been identified in these plants, especially antioxidant,
antimicrobial and topical and systemic anti-inflammatory activities. The aim of this study was to investigate the
mutagenicity and antimutagenicity of hydroalcoholic leaf extracts of six species of Byrsonima: B. verbascifolia,
B. correifolia, B. coccolobifolia, B. ligustrifolia, B. fagifolia and B. intermedia by the Salmonella microsome assay
(Ames test).
Methods: Mutagenic and antimutagenic activity was assessed by the Ames test, with the Salmonella typhimurium tester
strains TA100, TA98, TA97a and TA102, with (+S9) and without (−S9) metabolization, by the preincubation method.
Results: Only B. coccolobifolia and B. ligustrifolia showed mutagenic activity. However, the extracts of B. verbascifolia,
B. correifolia, B. fagifolia and B. intermedia were found to be strongly antimutagenic against at least one of the
mutagens tested.
Conclusions: These results contribute to valuable data on the safe use of medicinal plants and their potential
chemopreventive effects. Considering the excellent antimutagenic activities extracted from B. verbascifolia, B. correifolia,
B. fagifolia and B. intermedia, these extracts are good candidate sources of chemopreventive agents. However, B.
coccolobifolia and B. ligustrifolia showed mutagenic activity, suggesting caution in their use.
Keywords: Salmonella/microsome assay, Chemoprevention, Medicinal plantsBackground
The use of medicinal plants in folk medicine is based on
empirical knowledge gathered for centuries by diverse
ethnic groups. This knowledge, based on daily experi-
ence and passed down from generation to generation,
constitutes the origin of modern medicine [1,2].
Byrsonima is a genus of Neotropical trees and shrubs
known for yellow, cherry-sized fruits. In various regions
of Brazil, several species of this genus are widely used in
the treatment of gastrointestinal problems. Research has
confirmed a number of different biological activities in* Correspondence: flaviabiomed@yahoo.com.br
1Department of Biological Sciences, Faculty of Pharmaceutical Sciences of
Araraquara, UNESP- São Paulo State University, Rodovia Araraquara-Jaú, km 1,
14801-902 Araraquara, São Paulo, Brazil
Full list of author information is available at the end of the article
© 2014 Espanha et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.these plants, especially antioxidant, antimicrobial and
topical and systemic anti-inflammatory activities. Phyto-
chemically, this genus has been noted for the presence
of flavonoids and triterpenoids [3].
In previous studies, the methanolic (MeOH) leaf ex-
tract of B. crassa showed mutagenic activity in the Ames
test with Salmonella typhimurium strain TA98, without
the metabolic activation system (S9), and amentoflavone,
one of the metabolites isolated from the ethyl acetate
fraction of this species, gave positive results for mutage-
nicity [4], while the MeOH extract of B. intermedia
demonstrated signs of mutagenic activity in the Salmon-
ella strains TA98 and TA100 [5].
To complement the studies with the genus Byrsonima,
we also tested MeOH and chloroform extracts of
B. basiloba for mutagenicity and antimutagenicity. Nol Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ever, both extracts showed antimutagenic activity against
direct and indirect mutagens [6].
Considering the popular use of these plants, the risk of
using medicinal extracts without detailed investigation
and the valuable role of chemopreventive substances,
the aim of this study was to assess the mutagenic activity
of hydroalcoholic extracts of leaves of six Byrsonima
species (B. verbascifolia, B. correifolia, B. coccolobifolia,
B. ligustrifolia, B. fagifolia and B. intermedia) by the Ames
test, and to identify protective activity in these species
against the mutagenicity of the direct and indirect-acting
mutagens, 4-nitro- o-phenylenediamine (NPD), mitomycin
C (MMC), benzo[a]pyrene (B[a]P) and aflatoxin B1 (AFB1).
Methods
Chemicals
Dimethylsulfoxide (DMSO), nicotinamide adenine dinu-
cleotide phosphate sodium salt (NADP), D-glucose-6-
phosphate disodium salt, magnesium chloride, L-histidine
monohydrate, D-biotin, sodium azide (NaN3), 2-anthramine
(2-AA), NPD, MMC, 2-aminofluorene (2-AF), B[a]P and
AFB1 were purchased from Sigma Chemical Co (St. Louis,
MO, USA). Oxoid Nutrient Broth No. 2 (Oxoid, England)
was used as the bacterial culture medium. D-Glucose,
magnesium sulfate, citric acid monohydrate, anhydrous
dibasic potassium phosphate, sodium ammonium phos-
phate, monobasic sodium phosphate, dibasic sodium phos-
phate and sodium chloride were purchased from Merck
(Whitehouse Station, NJ, USA).
Plant material and extraction
Aerial parts of each species were collected in the states
of São Paulo, Tocantins and Piauí, Brazil, as reported in
Table 1, which also has details of the voucher specimens.
The leaves were separated from the aerial parts, dried
at 40°C to constant mass and then pulverized and
stored in the dark, under cool, dry conditions, until
used. Hydroalcoholic extracts were prepared in 7:3 (v/v)
EtOH/H2O, in a stainless steel percolator (20 L). TheTable 1 Plant material
Species and identification authority Voucher specimen number
B. coccolobifolia Kunth. 1397
B. intermedia A. Juss. 1426
B. correifolia A. Juss. 27151
B. fagifolia Nied. 743
B. verbascifolia (L.) DC. 481
B. ligustrifolia Mart. 24164solvent was added to the leaf powder and left standing
for 2 h, before packing the percolator, with a solvent:
leaf powder ratio of 5:1 (w/w). The percolation was per-
formed at a moderate flow rate of 2 mL/min/kg. The
solvent was eliminated from the extract in a rotatory
evaporator (Heidolph Laborota 4001), equipped with
low- pressure pump control with a Heidolph Rotavac
Control valve. The residual water extract was dried in a
Micro Module freeze-dryer (Savant Instruments Inc.).
The dried extract was powdered and stored in amber
bottles at 4°C.
Mutagenicity test
Mutagenicity was assessed by the Ames test (Salmon-
ella/microsome assay), with a preincubation for 20 min,
with (+S9) and without (−S9) metabolic activation. The
Salmonella typhimurium tester strains, TA98, TA100,
TA97a and TA102, were kindly provided by Dr. B.N.
Ames (Berkeley, CA, USA) [7,8]. These strains were grown
overnight from frozen cultures for 12–14 h in Oxoid Nu-
trient Broth No. 2. The metabolic activation mixture (S9
fraction), prepared from livers of Sprague–Dawley rats
treated with the polychlorinated biphenyl mixture Aroclor
1254 (500 mg/kg), was purchased from Molecular Toxicol-
ogy Inc. (Boone, NC, USA) and freshly prepared before
each test. The metabolic activation system consisted of
4% S9 fraction, 1% 0.4 M MgCl2, 1% 1.65 M KCl, 0.5% 1 M
D-glucose-6-phosphate disodium and 4% 0.1 M NADP,
50% 0.2 M phosphate buffer and 39.5% sterile distilled
water [8].
To assay mutagenic activity, five different concentrations
of each dry extract (0.20-16.7 mg/plate for B. verbascifolia,
0.52-16.7 mg/plate for B. correifolia, 0.52-16.0 mg/plate
for B. coccolobifolia, 0.02-18.0 mg/plate for B. ligustrifolia,
0.6-5.0 mg/plate for B. fagifolia and B. intermedia), dis-
solved in DMSO, were tested. The extract concentrations
were selected on the basis of a preliminary toxicity test. In
all subsequent assays, the upper limit of the dose range
tested was either the highest non-toxic dose or the lowest
toxic dose determined in this preliminary assay. ToxicityCollection site Herbarium (where voucher
specimen is deposited)
Itirapina, SP, Brazil UNICAMP Herbarium
Pratânia, SP, Brazil UNICAMP Herbarium
José de Freitas, PI, Brazil Graziella Barroso Herbarium, at
Federal University of Piauí
Porto Nacional, TO, Brazil Herbarium of the Federal
University of Tocantins
Porto Nacional, TO, Brazil Herbarium of the Federal
University of Tocantins
Pratânia, SP, Brazil Herbarium of São Paulo State
University, at Botucatu, SP.
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dine revertants (His+) or as a thinning of the auxotrophic
background lawn.
The various amounts of extracts to be tested, dissolved
in DMSO, were added to 0.5 mL of 0.2 M phosphate
buffer or to 0.5 mL of 4% S9 mixture, plus 0.1 mL of bac-
terial culture and then incubated at 37°C for 20–30 min.
Thereafter, 2 ml of top agar were added, and the mixture
poured on to a plate containing minimal agar.
The plates were incubated at 37°C for 48 h and the
His + revertant colonies were counted manually. All ex-
periments were done in triplicate. The standard mutagens
used as positive controls in experiments without the S9
mix were NPD (10 μg/plate) for TA98 and TA97a, NaN3
(2.5 μg/plate) for TA100 and MMC (0.5 μg/plate) for
TA102. In experiments with S9 activation, 2-AA (1.5 μg/
plate) was used with TA98, TA97a and TA100 and 2-AF
(5 μg/plate) with TA102. DMSO (100 μL/plate) served as
negative (solvent) control.
Antimutagenicity test
Only extracts considered non-mutagenic were subject
to this test employing the method of preincubation in
plates, developed by Maron and Ames [8]. Five differ-
ent concentrations of extracts (0.013-2.000 mg/plate for
B. verbascifolia, 0.008-4.000 mg/plate for B. correifolia,
0.010-0.500 mg/plate for B. fagifolia and 0.007-0.250 mg/
plate for B. intermedia) were associated with known mu-
tagens in tests with and without metabolic activation,
using S. typhimurium tester strains TA98, TA100 and
TA102. In the tests without metabolic activation, the
mutagen NPD (10.0 μg/plate) was used for TA98 and
MMC (0.5 μg/plate) for TA102, while in those with meta-
bolic activation, 1.0 μg/plate of B[a]P was used for TA98
and 0.5 μg/plate of AFB1 for TA100. The extracts were
mixed with 0.5 mL of 0.2 M phosphate buffer, or 0.5 mL
of 4% S9 mixture for metabolic activation, 0.1 mL of
bacterial culture and the mutagen and incubated at 37°C
for 20–30 min. After incubation, 2 mL of top agar was
added, and the content of each tube was lightly homoge-
nized and poured onto a plate of glucose minimal agar.
After solidification of the top agar, the plates were incu-
bated for 48 h at 37°C, and the number of revertant
colonies per plate was counted. The entire assay was per-
formed in triplicate [6,9].
Data analysis
The mutagenic activity results were analyzed with the stat-
istical software package Salanal 1.0 (U.S. Environmental
Protection Agency, Monitoring Systems Laboratory, Las
Vegas, NV, from the Research Triangle Institute, RTP, NC,
USA), adopting the model of Bernstein et al. [10]. The data
(revertants/plate) were assessed by analysis of variance
(ANOVA), followed by linear regression. The mutagenicityratio (MR) was also calculated for each concentration
tested; MR is the average number of revertants per test
plate divided by the average number of revertants per
negative (solvent) control plate. The sample was consid-
ered mutagenic when a dose–response relationship was de-
tected and a two-fold increase in the number of revertants
(MR ≥ 2) was observed for at least one concentration [7].
The antimutagenic activity results were analyzed with
the statistical software GraphPad Prism 5. The data
(revertants/plate) were assessed by analysis of variance
(one-way ANOVA), followed by Tukey’s test. The anti-
mutagenicity results were expressed as percent inhib-
ition (the ability of the compounds to inhibit the action
of the known mutagen), calculated as described by
Tachino et al. [11]:
Inhibition %ð Þ ¼ 100‐ T=Mð Þ  100½ 
where T is the number of revertant colonies in a plate
containing mutagen and compounds and M is the num-
ber of revertant colonies in a plate containing the muta-
gen alone.
Results were interpreted as no antimutagenic effect
when the inhibition was lower than 25%, a moderate ef-
fect for a value between 25% and 40% and strong anti-
mutagenicity for values greater than 40% [9,12].
Cell viability was also determined in each antimuta-
genesis experiment, to assess the potential bactericidal
effect of the mutagens and associations. A sample was
considered bactericidal when the number of viable bac-




Table 2 shows the mean number of revertants/plate (M),
the standard deviation (SD) and the mutagenic ratio (MR)
after the treatments with the six extracts, observed in S.
typhimurium strains TA98, TA100, TA97a and TA102, in
the presence (+S9) and absence (−S9) of metabolic activa-
tion. The results showed that only B. coccolobifolia and
B. ligustrifolia extracts induced an increase in the number
of revertant colonies relative to the negative control, indi-
cating mutagenic activity. B. coccolobifolia, in the absence
of S9, showed activity in the strain TA98, with a dose–
response relationship reaching a mutagenic ratio of 2.8. In
the presence of S9, in the same strain, at all concentrations
tested, this extract reached a mutagenic ratio higher than
2.0. B. ligustrifolia, in TA98 without S9, reached a muta-
genic ratio of 2.0 at the two highest concentrations tested.
None of the other species extracts induced twofold or
greater increase in the mean number of revertants relative
to the negative control group, in the presence or absence
of S9.
Table 2 Mutagenic activity expressed as mean number of revertants/plate ± standard deviation and mutagenicity ratio (in brackets) of hydroalcoholic leaf
extracts of six Byrsonima species







- S9 + S9 - S9 + S9 - S9 + S9 - S9 + S9
B. verbascifolia
0.0a 17 ± 4 68 ± 1 0.0a 113 ± 16 114 ± 11 0.0a 81 ± 6 121 ± 20 0.0a 381 ± 43 341 ± 34
2.1 15 ± 3 (0.9) 67 ± 2 (1.0) 0.4 91 ± 8 (0.8) 121 ± 12 (1.1) 0.2 78 ± 3 (1.0) 137 ± 16 (1.1) 0.4 369 ± 3 (1.0) 387 ± 20 (1.1)
4.2 24 ± 6 (1.4) 75 ± 5 (1.1) 0.7 107 ± 20 (1.0) 124 ± 10 (1.1) 0.4 97 ± 2 (1.2) 140 ± 10 (1.2) 0.7 305 ± 16 (0.8) 445 ± 32 (1.3)
8.3 18 ± 6 (1.0) 81 ± 3 (1.2) 1.5 106 ± 2 (0.9) 99 ± 4 (0.9) 0.8 117 ± 2 (1.4) 146 ± 7 (1.2) 1.5 368 ± 36 (1.0) 353 ± 29 (1.0)
12.5 23 ± 3 (1.3) 61 ± 4 (0.9) 2.2 105 ± 4 (0.9) 104 ± 5 (0.9) 1.1 109 ± 6 (1.3) 166 ± 12 (1.4) 2.2 322 ± 45 (0.9) 344 ± 45 (1.0)
16.7 29 ± 12 (1.7) 50 ± 1 (0.7) 3.0 110 ± 9 (1.0) 93 ± 3 (0.8) 1.6 94 ± 5 (1.2) 169 ± 39 (1.4) 3.0 373 ± 11 (1.0) 350 ± 27 (1.0)
C + 720 ± 28b 500 ± 32c C + 1375 ± 35d 1387 ± 37c C + 1115 ± 25b 1450 ± 70c C + 1468 ± 53e 1403 ± 33f
B. correifolia
0.0a 20 ± 4 68 ± 1 0.0a 93 ± 6 114 ± 11 0.0a 172 ± 2 99 ± 1 0.0a 352 ± 30 435 ± 43
2.1 16 ± 3 (0.8) 86 ± 6 (1.3) 0.5 73 ± 3 (0.8) 103 ± 5 (0.9) 0.5 185 ± 6 (1.1) 85 ± 4 (0.9) 0.5 397 ± 11 (1.1) 608 ± 45 (1.4)
4.2 18 ± 2 (0.9) 80 ± 3 (1.2) 1.0 90 ± 10 (1.0) 106 ± 8 (0.9) 1.0 165 ± 11 (1.0) 123 ± 11 (1.3) 1.0 386 ± 33 (1.1) 564 ± 35 (1.3)
8.3 27 ± 3 (1.3) 66 ± 6 (1.0) 2.1 93 ± 8 (1.0) 96 ± 9 (0.8) 2.1 166 ± 18 (1.0) 135 ± 4 (1.4) 2.1 413 ± 16 (1.2) 484 ± 33 (1.1)
12.5 37 ± 10 (1.8) 62 ± 3 (0.9) 3.1 94 ± 11 (1.0) 115 ± 12 (1.0) 3.1 186 ± 5 (1.1) 110 ± 4 (1.1) 3.1 333 ± 50 (1.0) 354 ± 38 (0.8)
16.7 31 ± 6 (1.5) 60 ± 9 (0.9) 4.2 65 ± 6 (0.7) 94 ± 4 (0.8) 4.2 143 ± 10 (0.8) 134 ± 5 (1.4) 4.2 285 ± 21 (0.8) 322 ± 32 (0.7)
C + 730 ± 28b 500 ± 32c C + 1250 ± 35d 700 ± 37c C + 950 ± 25b 1450 ± 70c C+ 1468 ± 53e 1403 ± 33f
B. coccolobifolia
0.0a 37 ± 8 24 ± 4 0.0a 112 ± 13 92 ± 9 0.0a 172 ± 2 123 ± 15 0.0a 406 ± 11 341 ± 34
2.0 56 ± 3* (1.5) 56 ± 6**(2.3) 0.5 115 ± 10 (1.0) 102 ± 12 (1.1) 0.5 129 ± 15 (0.7) 144 ± 11 (1.2) 0.5 345 ± 8 (0.9) 386 ± 17 (1.1)
4.0 61 ± 8* (1.7) 51 ± 1**(2.1) 1.0 135 ± 18 (1.2) 115 ± 7 (1.3) 1.0 145 ± 10 (0.8) 163 ± 11 (1.3) 1.0 338 ± 13 (0.8) 366 ± 12 (1.1)
8.0 70 ± 9* (1.9) 67 ± 13*(2.8) 2.1 154 ± 25 (1.4) 110 ± 11 (1.2) 2.1 175 ± 15 (1.0) 208 ± 29* (1.7) 2.1 350 ± 23 (0.9) 330 ± 24 (1.0)
12.0 102 ± 10**(2.8) 64 ± 9**(2.6) 3.1 170 ± 14 (1.5) 108 ± 8 (1.2) 3.1 214 ± 5 (1.2) 215 ± 13**(1.8) 3.1 355 ± 13 (0.9) 297 ± 8 (0.9)
16.0 67 ± 10* (1.9) 63 ± 13*(2.6) 4.2 143 ± 27 (1.3) 115 ± 18 (1.3) 4.2 190 ± 7 (1.1) 237 ± 34* (1.9) 4.2 358 ± 10 (0.9) 261 ± 2 (0.8)
























Table 2 Mutagenic activity expressed as mean number of revertants/plate ± standard deviation and mutagenicity ratio (in brackets) of hydroalcoholic leaf
extracts of six Byrsonima species (Continued)
B. ligustrifolia
0.0a 18 ± 3 24 ± 4 0.0a 210 ± 33 87 ± 15 0.0a 110 ± 9 115 ± 1 0.0a 262 ± 25 407 ± 30
2.2 21 ± 1 (1.2) 22 ± 5 (0.9) 0.08 226 ± 13 (1.1) 114 ± 13 (1.3) 0.16 106 ± 5 (1.0) 132 ± 12 (1.2) 0.02 330 ± 16 (1.3) 379 ± 45 (0.9)
4.0 22 ± 1 (1.3) 27 ± 8 (1.1) 0.16 211 ± 12 (1.0) 98 ± 6 (1.1) 0.31 109 ± 8 (1.0) 136 ± 8 (1.2) 0.04 232 ± 2 (0.9) 382 ± 21 (0.9)
9.0 20 ± 2 (1.1) 38 ± 7 (1.6) 0.31 224 ± 37 (1.1) 90 ± 9 (1.0) 0.62 127 ± 7 (1.2) 132 ± 19 (1.2) 0.08 244 ± 25 (0.9) 411 ± 20 (1.0)
13.5 35 ± 6* (2.0) 34 ± 9 (1.4) 0.47 227 ± 24 (1.1) 94 ± 3 (1.1) 0.94 90 ± 6 (0.8) 145 ± 17 (1.3) 0.12 243 ± 22 (0.9) 395 ± 12 (1.0)
18.0 36 ± 5* (2.0) 32 ± 2 (1.3) 0.62 209 ± 11 (1.0) 93 ± 16 (1.1) 1.25 121 ± 1 (1.1) 133 ± 4 (1.2) 0.16 258 ± 11 (1.0) 328 ± 15 (0.8)
C + 300 ± 12b 227 ± 16c C + 919 ± 17d 987 ± 32c C + 1110 ± 32b 1036 ± 41c C + 1349 ± 45e 1464 ± 43f
B. fagifolia
0.0a 23 ± 2 22 ± 3 0.0a 124 ± 10 100 ± 7 0.0a 154 ± 10 164 ± 23 0.0a 321 ± 39 300 ± 58
0.6 26 ± 1 (1.1) 28 ± 4 (1.3) 0.6 146 ± 13 (1.2) 121 ± 9 (1.2) 0.6 190 ± 16 (1.2) 175 ± 21 (1.1) 0.6 396 ± 38 (1.2) 269 ± 67 (0.9)
1.2 23 ± 3 (1.0) 29 ± 2 (1.3) 1.2 127 ± 5 (1.0) 115 ± 3 (1.2) 1.2 172 ± 7 (1.1) 176 ± 25 (1.1) 1.2 385 ± 31 (1.2) 332 ± 23 (1.1)
2.5 27 ± 2 (1.2) 24 ± 8 (1.1) 2.5 125 ± 18 (1.0) 126 ± 9 (1.3) 2.5 171 ± 16 (1.1) 194 ± 11 (1.2) 2.5 356 ± 25 (1.1) 320 ± 54 (1.1)
3.7 38 ± 8* (1.7) 25 ± 2 (1.1) 3.7 139 ± 23 (1.1) 117 ± 24 (1.2) 3.7 176 ± 12 (1.1) 184 ± 6 (1.1) 3.7 261 ± 47 (0.8) 273 ± 69 (0.9)
5.0 38 ± 6* (1.7) 29 ± 4 (1.3) 5.0 155 ± 5 (1.3) 107 ± 10 (1.1) 5.0 172 ± 11 (1.1) 176 ± 20 (1.1) 5.0 277 ± 64 (0.9) 221 ± 43 (0.7)
C+ 947 ± 88b 767 ± 115c C+ 1682 ± 98 d 1956 ± 78c C + 1766 ± 49b 1989 ± 89c C + 2656 ± 60e 2932 ± 97f
B. intermedia
0.0a 22 ± 5 21 ± 8 0.0a 151 ± 14 151 ± 4 0.0a 176 ± 10 249 ± 22 0.0a 303 ± 99 396 ± 12
0.6 23 ± 3 (1.0) 21 ± 7 (1.0) 0.6 162 ± 7 (1.1) 169 ± 12 (1.1) 0.6 187 ± 25 (1.1) 304 ± 28 (1.2) 0.6 274 ± 36 (0.9) 427 ± 66 (1.1)
1.2 28 ± 4 (1.3) 21 ± 3 (1.0) 1.2 165 ± 5 (1.1) 157 ± 15 (1.0) 1.2 228 ± 16 (1.3) 315 ± 7 (1.3) 1.2 243 ± 19 (0.8) 380 ± 28 (1.0)
2.5 30 ± 3 (1.4) 17 ± 6 (0.8) 2.5 142 ± 10 (0.9) 160 ± 5 (1.1) 2.5 201 ± 26 (1.1) 261 ± 18 (1.0) 2.5 285 ± 64 (0.9) 401 ± 60 (1.0)
3.7 28 ± 1 (1.3) 25 ± 8 (1.2) 3.7 155 ± 18 (1.0) 150 ± 4 (1.0) 3.7 199 ± 7 (1.1) 270 ± 19 (1.1) 3.7 345 ± 61 (1.1) 351 ± 63 (0.9)
5.0 35 ± 5* (1.6) 17 ± 2 (0.8) 5.0 163 ± 8 (1.1) 140 ± 7 (0.9) 5.0 176 ± 23 (1.0) 261 ± 13 (1.0) 5.0 302 ± 53 (1.0) 281 ± 72 (0.7)
C + 872 ± 67b 736 ± 79c C + 1512 ± 64d 1500 ± 88c C+ 1196 ± 52b 1217 ± 69c C+ 2539 ± 187e 2114 ± 162f
aNegative Solvent Control: DMSO, 100 μL/plate; Positive Control (C +): b4-nitro-o-phenylenediamine, 10 μg/plate; c2- anthramine, 1.5 μg/plate; dSodium azide, 2.5 μg/plate, eMitomycin C, 0.5 μg/plate; f2-aminofluorene,
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The antimutagenic effect of each extract was assessed
from the mean number of revertants/plate, the standard
deviation (SD) and the percent inhibition (% I) of the
mutagenic activity of NPD, MMC, AFB1 and B[a]P on
treatment with the five concentrations of the extract.
The results are displayed in Table 3. B. verbascifolia ex-
tract can be considered a strong antimutagen against
NPD, as it showed more than 40% inhibition at two of
the concentrations tested. When tested with MMC, this
extract did not show antimutagenic activity; however,
with AFB1, all five concentrations tested showed more
than 40% inhibition, and concentrations in the range of
0.25-2 mg/plate achieved 91% inhibition, making the
extract a very strong antimutagen. Against B[a]P, the five
tested concentrations of the extract of B. verbascifolia also
showed more than 40% inhibition and the highest concen-
tration attained 82%, ranking it as strongly antimutagenic.
B. correifolia extract also showed strong antimutagenic
activity against NPD, as it induced more than 40% inhib-
ition at four of the five concentrations tested. However,
the extract was not antimutagenic against MMC. When
mixed with AFB1, all five tested concentrations of the ex-
tract showed inhibition exceeding 40%, reaching 80% at
one concentration. Thus, B. correifolia had strong antimu-
tagenic activity against this agent. Associated with B[a]P,
all five concentrations of the extract of B. correifolia tested
showed inhibition of revertants around 80%, reaching 83%
at one concentration, representing very high antimuta-
genicity. Although B. correifolia was not found to be anti-
mutagenic against MMC, it demonstrated a potential for
significant reduction in the numbers of revertants.
Extract of B. fagifolia and B. intermedia can be de-
scribed as moderately antimutagenic against NPD, as they
inhibited 36% and 30% of revertants, respectively. Against
MMC, these extracts showed no antimutagenic activity.
When combined with AFB1, these extracts showed 36%
and 32% inhibition, respectively, and can be considered
moderately antimutagenic. When mixed with B[a]P, the
two extracts induced inhibition greater than 40%, reaching
76% and 77%, respectively, and ranking them as strongly
antimutagenic.
Discussion
In Brazil, plants of the genus Byrsonima (Malpighiaceae)
represent a rich source of catechin and epicatechin de-
rivatives and are used in folk medicine for the treat-
ment of gastric ulcers, inflammation, skin infections,
fever and asthma. They are popularly known as “mur-
ici-vermelho” or “murici-cascudo” and grow wild in
the cerrado (savannah-like) vegetation of Brazil. Byrso-
nima species have been scientifically proven to possess
several pharmacological properties, such as antiulcero-
genic, mutagenic and antimicrobial activity [14].The results of this study demonstrate an absence of any
mutagenic activity in leaf extracts of B. verbascifolia,
B. correifolia, B. fagifolia and B. intermedia, at all the con-
centrations tested on the four S. typhimurium strains,
since the number of revertant colonies observed on each
test plate was less than twice that in the negative control
[7]. However, B. coccolobifolia extract doubled the number
of revertant colonies in strain TA98, both in the presence
and in the absence of metabolic activation, suggesting an
ability to cause frameshift mutations, before and even after
being metabolized. In strain TA97a, the dose–response for
B. coccolobifolia went up to a mutagenicity ratio of 1.9,
giving evidence of mutagenicity. B. ligustrifolia also dou-
bled the number of revertant colonies in strain TA98 in
the absence of metabolic activation and can be considered
an inducer of frameshift mutations.
In a previous study, we showed that a MeOH extract of
B. crassa exhibited mutagenic activity in the Ames test.
The following compounds were isolated from the acetate
fraction: quercetin-3-O-β-D-galactopyranoside, quercetin-
3-O-α-L-arabinopyranoside, amentoflavone, methyl gallate
and (+)-catechin. Among these, only amentoflavone ex-
hibited positive mutagenicity. Therefore, this compound
contributes to the mutagenic activity observed in the
MeOH extract [4].
In another study, MeOH, hydromethanol and chloro-
form extracts of B. intermedia were assessed for mutage-
nicity by the Ames test and mutagenic activity was not
positively identified, in any extract, but the MeOH
extract showed signs of mutagenicity to the strains TA98
(+S9,−S9) and TA100 (−S9). The values of the MR
were close to 2, and the dose–response effect was
significant. Phytochemical analysis of the MeOH extract
furnished (+)-catechin, (−)-epicatechin, quercetin-3-O-
β-D-galactopyranoside, methyl gallate, gallic acid, quercetin-
3-O-α-L-arabinopyranoside, amentoflavone, quercetin,
quercetin-3-O-(2”-O-galloyl)- β -galactopyranoside and
quercetin-3-O-(2”-O-galloyl)- α -arabinopyranoside [5].
Comparing the compounds in the MeOH extracts of
B. intermedia with those from B. crassa [15], similar
profiles were observed, but a difference was seen in the
flavonol concentration and the difference in the amento-
flavone content explained the results obtained. In B.
crassa, mutagenic activity was observed and the main
compound of the extract responsible for this effect was
amentoflavone [4]. In B. intermedia, this biflavonol is
also present, but in smaller amounts, explaining the
signs of mutagenic activity obtained in the assays with
Salmonella [5].
Quercetin is a compound that is always present in
Byrsonima extracts [4-6]. It is a flavonoid known for its
mutagenic potential. Resende et al. [16] showed that
quercetin is highly mutagenic in TA98, TA100 and TA102.
This compound has been observed to induce a mutation
Table 3 Antimutagenic activity expressed as mean number of revertants/plate (M) ± standard deviation (SD) and deg of growth inhibition of revertants
(%I), in combinations of four Byrsonima species hydroalcoholic extracts with direct and indirect mutagens
Mutagens (M) NPDb MMCc AFB1
d B[a]Pe
Strains TA 98 (-S9) TA 102 (-S9) TA 100 (+S9) TA 98 (+S9)
Treatment (mg/plate) M ± SD and (%I) Treatment (mg/plate) M ± SD and (%I) Treatment (mg/plate) M ± SD an (%I) Treatment (mg/plate) M ± SD and (%I)
B. verbascifolia
0a 18 ± 4 0a 487 ± 81 0a 114 ± 6 0a 36 ± 5
0.013 +Mb 483 ± 40** (45) 0.094 +Mc 1502 ± 138 (6) 0.125 +Md 213 ± 7*** ) 0.049 +Me 102 ± 24*** (44)
0.025 +Mb 454 ± 60*** (48) 0.188 +Mc 1296 ± 24 (19) 0.250 +Md 131 ± 27** 1) 0.098 +Me 78 ± 6*** (57)
0.050 +Mb 550 ± 41** (37) 0.375 +Mc 1366 ± 21 (15) 0.500 +Md 125 ± 16** 1) 0.195 +Me 85 ± 9*** (54)
0.100 +Mb 628 ± 138* (28) 0.750 +Mc 1380 ± 4 (14) 1.000 +Md 132 ± 13** 1) 0.390 +Me 41 ± 5*** (78)
0.200 +Mb 1001 ± 137 1.500 +Mc 1381 ± 58 (14) 2.000 +Md 132 ± 24** 1) 0.780 +Me 34 ± 7*** (82)
Mb 876 ± 30 Mc 1601 ± 226 Md 1399 ± 34 Me 184 ± 8
B. correifolia
0a 18 ± 4 0a 464 ± 48 0a 104 ± 15 0a 36 ± 5
0.013 +Mb 440 ± 57*** (50) 0.031 +Mc 1208 ± 15 (15) 0.008 +Md 353 ± 59** 0) 0.250 +Me 34 ± 6*** (82)
0.025 +Mb 426 ± 2*** (51) 0.063 +Mc 1126 ± 66* (20) 0.016 +Md 248 ± 38** 2) 0.500 +Me 31 ± 6*** (83)
0.050+ Mb 497 ± 39*** (43) 0.125 +Mc 1152 ± 74* (19) 0.031 +Md 370 ± 49** 8) 1.000 +Me 32 ± 6*** (82)
0.100+ Mb 593 ± 20*** (32) 0.250 +Mc 1205 ± 52 (15) 0.063 +Md 180 ± 57** 0) 2.000 +Me 31 ± 5*** (83)
0.200+ Mb 521 ± 61*** (41) 0.500 +Mc 1129 ± 146*(20) 0.125 +Md 206 ± 46** 7) 4.000 +Me 39 ± 3*** (79)
Mb 876 ± 30 Mc 1414 ± 61 Md 883 ± 80 Me 184 ± 8
B. fagifolia
0a 45 ± 8 0a 355 ± 36 0a 94 ± 12 0a 19 ± 7
0.030 +Mb 705 ± 72 (7) 0.010 +Mc 1579 ± 94 0.030 +Md 976 ± 38 (8 0.030 +Me 378 ± 49*** (41)
0.060+ Mb 612 ± 43 (19) 0.030 +Mc 1395 ± 70 0.060 +Md 915 ± 44 (1 0.060 +Me 405 ± 51*** (37)
0.120 +Mb 623 ± 38 (17) 0.060 +Mc 1499 ± 89 0.120 +Md 739 ± 40** 1) 0.120 +Me 332 ± 35*** (48)
0.250 +Mb 593 ± 51 (21) 0.120 +Mc 1432 ± 79 0.250 +Md 781 ± 52** 7) 0.250 +Me 268 ± 43*** (58)
0.500 +Mb 483 ± 40* (36) 0.250 +Mc 1440 ± 65 0.500 +Md 680 ± 36** 6) 0.500 +Me 157 ± 29*** (76)








































Table 3 Antimutagenic activity expressed as mean number of revertants/plate (M) ± standard deviation (SD) and degree of growth inhibition of revertants
(%I), in combinations of four Byrsonima species hydroalcoholic extracts with direct and indirect mutagens (Continued)
B. intermedia
0a 53 ± 12 0a 317 ± 55 0a 94 ± 12 0a 19 ± 7
0.010 +Mb 677 ± 67* (24) 0.007 +Mc 1593 ± 71 (5) 0.010 +Md 981 ± 61 (8) 0.010 +Me 338 ± 37*** (47)
0.030 +Mb 679 ± 61* (24) 0.010 +Mc 1584 ± 45 (5) 0.030 +Md 993 ± 32 (7) 0.030 +Me 385 ± 48*** (40)
0.060 +Mb 665 ± 82* (26) 0.030 +Mc 1504 ± 68 (10) 0.060 +Md 958 ± 20 (10) 0.060 +Me 293 ± 27*** (54)
0.120 +Mb 632 ± 54** (29) 0.060 +Mc 1443 ± 82 (14) 0.120 +Md 864 ± 39** (19) 0.120 +Me 253 ± 19*** (60)
0.250 +Mb 621 ± 42** (30) 0.120 +Mc 1409 ± 72 (16) 0.250 +Md 725 ± 23*** (32) 0.250 +Me 148 ± 23*** (77)
Mb 893 ± 79 Mc 1672 ± 102 Md 1064 ± 101 Me 640 ± 49
aNegative Solvent Control: DMSO, 100 μL/plate; Mutagens (M): b4-nitro-o-phenylenediamine, 10 μg/plate; cMitomycin C, 0.5 μg/plate; dAflatoxin B1, 0.5 μg/plate;
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mutagenic potential of this genus.
For the hydroalcoholic extract of B. intermedia and
B. fagifolia, the results obtained here are also similar to
results described for the MeOH extract [5,17]. This fact
suggests that the MeOH and hydroalcoholic extracts are
similar in composition.
The detection of genotoxicity is highly advisable, so as to
avoid the risk of genotoxic exposure to mutagens and car-
cinogens. However, some genotoxic compounds cannot be
completely avoided because they are air pollutants, or some
might be ingested as food contaminants. Also, some thera-
peutic drugs belong to an important group of genotoxic
compounds. Antimutagenicity studies have been developed
to diminish the risk in the event of genotoxic exposure
[18]. There have been several reports in the literature, that
medicinal plants or fruit juices have components such as
polyphenols, vitamins, chlorophylls, terpenes and unknown
organic compounds, which are described as antimutagens
and perhaps anticarcinogens [19].
In the present study, the B. verbascifolia and B. correi-
folia extracts acted as strong antimutagens against NPD,
with inhibition up to 48% and 51% of induced rever-
tants, respectively. B. fagifolia and B. intermedia were
moderately antimutagenic, and their percentages of in-
hibition reached 36% and 30%. These extracts were able
to prevent frameshift mutations.
When combined with MMC, none of the extracts could
be considered antimutagenic, although B. correifolia ex-
tract reduced significantly the number of revertants at
several doses.
Against AFB1, B. verbascifolia and B. correifolia ex-
tracts performed as strong antimutagens, reaching inhib-
ition levels of 91% and 80% of revertants, respectively. It
should be emphasized that when the concentration of
the B. verbascifolia extract was varied, the inhibition
remained at 91%, which reinforces its strongly protective
potential. B. fagifolia and B. intermedia were moderately
antimutagenic in these tests, reaching 36% and 32% in-
hibition, respectively. This demonstrates the potential of
these extracts to be used as protective agents against in-
direct mutagens, which require metabolic activation.
Against B[a]P, all the extracts showed strong antimuta-
genicity and may be able to prevent frameshift muta-
tions. B. verbascifolia reached a level of inhibition of 82%,
B. correifolia 83%, B. fagifolia 76% and B. intermedia 77%.
It should be emphasized that even when the concentration
of the B. correifolia extract was varied, the percentages of
inhibition remained very close to each other (at 82-83%),
confirming its protective potential.
In previous studies, no mutagenic activity was ob-
served in MeOH and chloroform extracts of B. basiloba,
however, both extracts showed antimutagenic activity.
The highest inhibition level (89%) was obtained with theMeOH extract, in the strain TA100 in the presence of
AFB1. Phytochemical analysis of these extracts revealed
the presence of n-alkanes, lupeol, ursolic and oleanolic
acid, (+)-catechin, quercetin-3-O-α-L-arabinopyranoside,
gallic acid, methyl gallate, amentoflavone, quercetin,
quercetin-3-O-(2”-O-galloyl)-β-D-galactopyranoside, and
quercetin-3-O-(2”-O-galloyl)-α-L-arabinopyranoside [6].
Rinaldo et al. [14] demonstrated that in MeOH extracts
and aqueous infusions from the leaves of five Byrsonima
species, only in B. coccolobifolia was it not possible to ob-
serve the presence of catechins and epicatechins. In the
other four species analyzed, it was found that the MeOH
extracts showed larger amounts of catechins than the in-
fusions, per gram of leaves. B. basiloba showed the highest
concentration of catechin diastereomers, followed by B.
verbascifolia, B. crassa and B. intermedia.
The results of this study are in agreement with those
in the above mentioned research. B. verbascifolia and B.
intermedia did not exhibit mutagenic activity, nor did B.
basiloba [6], but all of them were antimutagenic and
showed high concentrations of catechins [14], suggesting
that catechins are important in antimutagenic activity.
This point is corroborated by a study that claims that
catechins are already known for their antimutagenic and
cancer preventive properties [20,21].
The phytochemistry of all species analyzed to date in
the genus Byrsonima is similar; we suggest that all spe-
cies possess amentoflavone and quercetin, but in varied
amounts. Probably, B. coccolobifolia and B. ligustrifolia
possess higher concentrations of amentoflavone or quer-
cetin, because they were mutagenic, but all the other
species studied here probably possess a lower concentra-
tion of these flavonoids.
Although the mutagenic biflavonoid amentoflavone was
present in the non-mutagenic B. basiloba, the amount of
this compound found in the MeOH extract (1.79 mg/g of
MeOH extract) was much smaller than that found in the
(mutagenic) B. crassa (17.04 mg/g of MeOH extract) and
B. intermedia (13.70 mg/g of MeOH extract) extracts,
which showed weak signs of mutagenicity in an earlier
study [5,6].
Finally, we have to emphasize the excellent chemopre-
ventive ability of these extracts, especially with respect
to compounds that require metabolic activation. All ex-
tracts evaluated were considered strongly antimutagenic
against at least one of the tested mutagens.
The careful study of medicinal plants should be en-
couraged, because while many beneficial properties are
confirmed or discovered, as shown here, some species
may pose risks to users.
Conclusion
These results contribute valuable data on the safe use of me-
dicinal plants and some benefits, such as chemopreventive
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http://www.biomedcentral.com/1472-6882/14/182effects. Some medicinal plants should be used with cau-
tion by the population, such as B. coccolobifolia and
B. ligustrifolia, because they are mutagenic. However,
B. verbascifolia, B. correifolia, B. fagifolia and B. inter-
media were found to be strongly antimutagenic against
at least one of the mutagens tested and, given the out-
standing antimutagenic activities revealed in some tests,
these extracts are good candidates for development as
chemopreventive agents. Considering that medicinal
herbs contain complex mixtures of thousands of com-
ponents that can act alone or synergistically [22], it is
important to continue phytochemical studies of hydro-
alcoholic extracts, to provide the chemical profile of
the active species.
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